Telomir Pharmaceuticals (NASDAQ: TELO) has announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. The results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, a disease that shares many biological similarities with human osteosarcoma.
Osteosarcoma is a rare but aggressive bone cancer that primarily affects children and young adults in humans, and large-breed dogs in veterinary medicine. Current treatment options often involve surgery and chemotherapy, but survival rates for metastatic disease remain poor. The fact that Telomir-Zn demonstrated similar growth inhibition across species at low concentrations suggests a conserved mechanism of action that could be exploited for therapeutic benefit in both populations.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. The company said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC.
The news is significant for several reasons. First, it highlights the potential of Telomir-Zn as a multi-indication asset, with activity in osteosarcoma adding to its ongoing development in breast cancer. Second, it underscores the value of comparative oncology, where naturally occurring cancers in pets can serve as models for human disease, potentially accelerating drug development timelines. Third, it positions Telomir to pursue a dual-market strategy, addressing unmet needs in both veterinary and human oncology.
To view the full press release, visit https://nnw.fm/laeGH.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company's lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer.
NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company's newsroom at https://nnw.fm/TELO.
About NetworkNewsWire
NetworkNewsWire ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 888-902-4192 (U.S. Mobile Phones Only). For more information, please visit https://www.NetworkNewsWire.com. Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer.
